1. Home
  2. CRDF vs LPA Comparison

CRDF vs LPA Comparison

Compare CRDF & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.21

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

LPA

Logistic Properties of the Americas

HOLD

Current Price

$3.56

Market Cap

93.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDF
LPA
Founded
1999
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.2M
93.9M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
CRDF
LPA
Price
$1.21
$3.56
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$9.63
N/A
AVG Volume (30 Days)
1.7M
13.7K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
27.37
N/A
EPS
N/A
N/A
Revenue
$365,993.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.25
Revenue Growth
49.61
N/A
52 Week Low
$1.16
$2.04
52 Week High
$4.56
$7.51

Technical Indicators

Market Signals
Indicator
CRDF
LPA
Relative Strength Index (RSI) 34.42 64.81
Support Level N/A $2.56
Resistance Level $1.72 $3.76
Average True Range (ATR) 0.17 0.22
MACD -0.04 0.08
Stochastic Oscillator 7.15 54.75

Price Performance

Historical Comparison
CRDF
LPA

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

Share on Social Networks: